Roberto Bueno Filho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Roberto Bueno Filho has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Ana Maria Roselino
Department of Internal Medicine, Division of Dermatology, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
12 shared publications - Eduardo Antonio Donadi
Department of Medicine, Division of Clinical Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, Brazil
6 shared publications - Paulo Ricardo Criado
Centro Universitário Faculdade de Medicina do ABC, Santo André, SP, Brazil; Faculdade de Ciências Médicas de Santos (Fundação Lusíada), Santos, SP, Brazil
4 shared publications - Sebastian Vernal
Escritório de Excelência, Hospital Israelita Albert Einstein, São Paulo, Brazil
4 shared publications - Daniel Lorenzini
Department of Dermatology, Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil
3 shared publications - Hélio Amante Miot
Department of Infectology, Dermatology, Imaging Diagnosis and Radiotherapy, Faculty of Medicine, Universidade Estadual Paulista, Botucatu, SP, Brazil
3 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (6)
Successful long-term management of severe psoriasis with secukinumab after autologous hematopoietic stem cell transplantation for multiple myeloma: a case report
- 12 November 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (6)
Open AccessSuccessful long-term management of severe psoriasis with secukinumab after autologous hematopoietic stem cell transplantation for multiple myeloma: a case report
- 21 November 2025
- Published by Springer Nature in Inflammation Research
- Vol. 74 (1) , 168
The OX40-OX40L Co-stimulatory pathway in dermatology: emerging frontiers for therapeutic approaches
The OX40/OX40L co-stimulatory signaling pathway plays a crucial role in T cell activation, differentiation, expansion, and survival across various human tissues, including the skin and mucosal surfaces. Alterations in this pathway have been implicated in diverse immune-mediated skin conditions such as tumor microenvironments; atopic dermatitis, characterized by type 2 inflammation; psoriasis and hidradenitis suppurativa, associated with Th17 responses; vitiligo, involving dysregulated interferon-producing CD8+ T cells. The complex interplay between mast cells expressing OX40L and T cells expressing OX40, which in some contexts can inhibit regulatory T cell (Treg) function and promote Th17 differentiation, underscores the therapeutic potential of either antagonizing or agonizing this co-stimulatory pathway. In this review, we discuss selected dermatological diseases in which the OX40/OX40L axis appears relevant to their immunopathogenesis and may serve as a potential therapeutic target.
- 21 November 2025
- Published by Springer Nature in Inflammation Research
- Vol. 74 (1) , 168
The OX40-OX40L Co-stimulatory pathway in dermatology: emerging frontiers for therapeutic approaches
The OX40/OX40L co-stimulatory signaling pathway plays a crucial role in T cell activation, differentiation, expansion, and survival across various human tissues, including the skin and mucosal surfaces. Alterations in this pathway have been implicated in diverse immune-mediated skin conditions such as tumor microenvironments; atopic dermatitis, characterized by type 2 inflammation; psoriasis and hidradenitis suppurativa, associated with Th17 responses; vitiligo, involving dysregulated interferon-producing CD8+ T cells. The complex interplay between mast cells expressing OX40L and T cells expressing OX40, which in some contexts can inhibit regulatory T cell (Treg) function and promote Th17 differentiation, underscores the therapeutic potential of either antagonizing or agonizing this co-stimulatory pathway. In this review, we discuss selected dermatological diseases in which the OX40/OX40L axis appears relevant to their immunopathogenesis and may serve as a potential therapeutic target.
- Open Access
- 30 May 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (3) , 583-586
Eficácia de upadacitinibe no controle de dermatite atópica, doença de Crohn e hidradenite supurativa: um tratamento, múltiplas indicações
- 30 May 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (3) , 583-586
Open AccessEficácia de upadacitinibe no controle de dermatite atópica, doença de Crohn e hidradenite supurativa: um tratamento, múltiplas indicações
- Open Access
- 21 April 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (3) , 583-586
Efficacy of upadacitinib in the management of atopic dermatitis, Crohn’s disease, and hidradenitis suppurativa: one treatment, multiple indications
- 21 April 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (3) , 583-586
Open AccessEfficacy of upadacitinib in the management of atopic dermatitis, Crohn’s disease, and hidradenitis suppurativa: one treatment, multiple indications
- Open Access
- 1 November 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 99 (6) , 895-915
Atualização na patogênese da dermatite atópica
- 1 November 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 99 (6) , 895-915
Open AccessAtualização na patogênese da dermatite atópica
- Top Cited PapersOpen Access
- 12 August 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (6) , 895-915
Update on the pathogenesis of atopic dermatitis
- 12 August 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (6) , 895-915
Top Cited PapersOpen AccessUpdate on the pathogenesis of atopic dermatitis
- Open Access
- 1 May 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 99 (3) , 472-475
Leishmaniose cutânea na região malar assemelhando-se a carcinoma espinocelular em dois pacientes idosos
- 1 May 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 99 (3) , 472-475
Open AccessLeishmaniose cutânea na região malar assemelhando-se a carcinoma espinocelular em dois pacientes idosos
- Open Access
- 24 February 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (3) , 472-475
Cutaneous leishmaniasis on the malar region suggesting squamous cell carcinoma in two elderly patients
- 24 February 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (3) , 472-475
Open AccessCutaneous leishmaniasis on the malar region suggesting squamous cell carcinoma in two elderly patients
- Open Access
- 1 November 2023
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 98 (6) , 774-780
Desfechos da pulsoterapia com dexametasona‐ciclofosfamida comparando grupos de pênfigo vulgar e pênfigo foliáceo em estudo de coorte brasileiro
- 1 November 2023
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 98 (6) , 774-780
Open AccessDesfechos da pulsoterapia com dexametasona‐ciclofosfamida comparando grupos de pênfigo vulgar e pênfigo foliáceo em estudo de coorte brasileiro
- Open Access
- 22 June 2023
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 98 (6) , 774-780
Dexamethasone-cyclophosphamide pulse therapy outcomes comparing pemphigus vulgaris and pemphigus foliaceus groups in a Brazilian cohort study
- 22 June 2023
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 98 (6) , 774-780
Open AccessDexamethasone-cyclophosphamide pulse therapy outcomes comparing pemphigus vulgaris and pemphigus foliaceus groups in a Brazilian cohort study